Liver cancer international最新文献

{"title":"Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma","authors":"Simon Gray,&nbsp;Angela Lamarca,&nbsp;Mairéad G. McNamara,&nbsp;Julien Edeline,&nbsp;Karen Piper-Hanley,&nbsp;Juan W. Valle,&nbsp;Richard A. Hubner","doi":"10.1002/lci2.62","DOIUrl":"10.1002/lci2.62","url":null,"abstract":"<p>Hepatocellular carcinoma (HCC) is a growing health concern, with an estimated global incidence of over 1 million by 2025. In its intermediate and advanced stages, HCC remains a challenging condition to treat, despite a recently expanded array of systemic therapies, which continues to grow. Extensive efforts have accordingly been made to identify predictive factors to guide treatment decisions. However, currently, only one predictive biomarker is in widespread clinical use, namely elevated alpha-fetoprotein for second-line systemic therapy with ramucirumab. This article reviews known prognostic and predictive biomarkers for patients with HCC who are treated with locoregional and systemic therapies, including recent controversies around the potential impact of HCC aetiology on the efficacy of systemic therapies.</p>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"4 1","pages":"13-27"},"PeriodicalIF":0.0,"publicationDate":"2022-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.62","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43237249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ALBI grade predicts suitability for further systemic therapy following sorafenib in patients with advanced hepatocellular carcinoma","authors":"Omar Fakih,&nbsp;Suraiya S. Haddad,&nbsp;Sophie Walker,&nbsp;Julien Edeline,&nbsp;Florien Estrade,&nbsp;Xin Wang,&nbsp;Angela Lamarca,&nbsp;Mairéad G. McNamara,&nbsp;Juan W. Valle,&nbsp;Richard A. Hubner","doi":"10.1002/lci2.61","DOIUrl":"10.1002/lci2.61","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background &amp; Aims</h3>\u0000 \u0000 <p>Preserved performance status (PS) and liver function are required for systemic therapy in patients with advanced hepatocellular carcinoma (aHCC). We investigated the frequency of suitability for further systemic therapies following sorafenib in aHCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Demographic, tumour and therapy-related data were collected retrospectively for patients with aHCC who received sorafenib at a UK tertiary referral centre (training cohort), and an independent French centre (validation cohort). The primary endpoint was percentage of patients with Child-Pugh class A (CP-A) liver disease and PS 0–1 after sorafenib discontinuation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sorafenib was received by 182 patients. After sorafenib discontinuation, 93 patients (51%) were CP-A and 60 patients (33%) were PS 0–1; 43 patients (24%) were both CP-A and PS 0–1. On multivariable analysis, patients with Albumin-Bilirubin (ALBI) score of 1 at time of sorafenib commencement were more likely to be suitable for post-sorafenib therapy, (44% grade 1 vs 15% grade 2) (OR 3.76, 95%CI 1.72–8.25, <i>P</i> = .0009). In the validation cohort of 216 patients baseline ALBI grade was also significantly associated with suitability for further systemic therapy (<i>P</i> = .008).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Most patients with aHCC are not suitable for further systemic therapy after sorafenib, but those with ALBI grade 1 have a greater likelihood of suitability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"4 1","pages":"5-12"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.61","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42595039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical factors associated with early disease progression after radioembolization for hepatocellular carcinoma and feasibility of post-progression systemic therapy","authors":"Charlotte Van Laeken,&nbsp;Thibault Taelman,&nbsp;Sarah Cappuyns,&nbsp;Geert Maleux,&nbsp;Vincent Vandecaveye,&nbsp;Chris Verslype,&nbsp;Christophe Deroose,&nbsp;Jeroen Dekervel","doi":"10.1002/lci2.60","DOIUrl":"10.1002/lci2.60","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Radioembolization (RE) for unresectable hepatocellular carcinoma (HCC) can provide clinical benefit for well-selected patients, whilst in others, rapid disease progression is observed. As an alternative for this patient population, new potent systemic treatment options are emerging. We aimed to identify the clinical factors associated with rapid progression following RE and assess the feasibility of starting a systemic treatment after progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort study of patients with unresectable HCC undergoing RE at a single referral centre between January 2009 and December 2018. Progression-free and overall survival times were calculated. Uni- and multivariate cox regression analysis was used to assess factors associated with poor outcomes. Charts were reviewed for post-progression treatment strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 116 patients with unresectable HCC were included. Median PFS after RE was 6.7 months (95% CI 3.97–9.37), which varied significantly (<i>P</i> &lt; .001) with Eastern Cooperative Oncology Group Performance Status (EGOC PS) (ECOG 0, 20.9 months [95% CI 8.6–33.2]; ECOG 1, 7.7 months [95% CI 3.1–12.1]; ECOG 2, 4.4 months [95% CI 1.7–7]). This association remained significant after multivariate testing, together with the number of HCC lesions (<i>P</i> = .017) and α-FP (<i>P</i> = .050). Progressive disease after RE occurred in 82 patients, of whom only 40 received subsequent systemic treatment. Again, ECOG PS at the time of progression was significantly better for patients who did receive systemic treatment versus those who did not (<i>P</i> = .002).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Patients with unresectable HCC, impaired general condition and multinodular disease have inferior outcomes after radioembolization. After RE, close monitoring of patient performance status, liver function and cancer control is warranted to allow timely initiation of systemic treatment when indicated.</p>\u0000 </section>\u0000 </div>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 3","pages":"128-136"},"PeriodicalIF":0.0,"publicationDate":"2022-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.60","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42124658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning and biomarkers in hepatocellular carcinoma: The future is now","authors":"F. Ponziani, E. Giannini, Q. Lai","doi":"10.1002/lci2.67","DOIUrl":"https://doi.org/10.1002/lci2.67","url":null,"abstract":"serum, urine, and tissue samples).","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43330134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Issue Information","authors":"","doi":"10.1002/lci2.30","DOIUrl":"https://doi.org/10.1002/lci2.30","url":null,"abstract":"","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47650407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosing, efficacy and safety of lenvatinb in the real-world treatment of hepatocellular carcinoma: Results from a Canadian database","authors":"Carla Pires Amaro,&nbsp;Michael J. Allen,&nbsp;Jennifer J. Knox,&nbsp;Erica S. Tsang,&nbsp;Howard J. Lim,&nbsp;Richard M. Lee-Ying,&nbsp;Kelvin W. Chan,&nbsp;Jessica Qian,&nbsp;Brandon M. Meyers,&nbsp;Alia Thawer,&nbsp;Sulaiman M. S. Al-Saadi,&nbsp;Tina Hsu,&nbsp;Ravi Ramjeesingh,&nbsp;Hatim Karachiwala,&nbsp;Tasnima Abedin,&nbsp;Vincent C. Tam","doi":"10.1002/lci2.59","DOIUrl":"10.1002/lci2.59","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>A phase 3 trial showed lenvatinib to be effective and safe in the treatment of unresectable hepatocellular carcinoma (HCC), however, its performance in the real world and effect of dosing on survival are unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From July 2018 to June 2020, HCC patients treated with lenvatinib from 10 Canadian cancer centres were included. Overall survival (OS) and progression-free survival (PFS) were retrospectively analysed and compared across first- and later lines use of lenvatinib. In patients receiving lenvatinib first-line, OS between different mean dose intensities and starting doses were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 220 patients were included, of which 79% received lenvatinib as first-line therapy. For first-line versus later line treatment, median OS was 12.5 versus 11.8 months (<i>P</i> = .83) and median PFS was 7.6 versus 4.6 months (<i>P</i> = .27) respectively. Of patients receiving lenvatinib first-line, 54% started at full dose according to their weight. Median OS for patients starting lenvatinib at full- and reduced-dose was 12.3 and 15.8 months (<i>P</i> = .75) respectively. Median OS for patients with a mean dose intensity &gt;66.7% compared ≤66.7% was 13.7 and 7.7 months (<i>P</i> = .01). In the multivariate analysis, dose intensity (&gt;66.7 vs ≤66.7%) did not predict for OS [HR 0.70, 95% CI 0.42–1.18; <i>P</i> = .18]. The most common side effects were fatigue (59%), hypertension (41%) and decreased appetite (25%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Lenvatinib appears to be effective in real-world practice regardless of the line of therapy. Dose modifications at the start or during treatment did not appear to significantly affect survival.</p>\u0000 </section>\u0000 </div>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 3","pages":"119-127"},"PeriodicalIF":0.0,"publicationDate":"2022-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.59","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43812995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver ultrasound in cirrhosis is inadequate for hepatocellular carcinoma surveillance compared to magnetic resonance imaging","authors":"Nishal Ravindran, Amol Agarwal, Feng Li, P. Thuluvath","doi":"10.1002/lci2.57","DOIUrl":"https://doi.org/10.1002/lci2.57","url":null,"abstract":"The guidelines recommend surveillance with liver ultrasound (US) for early detection of hepatocellular carcinoma (HCC). The accuracy of US is operator‐dependent and is limited in those with severe obesity or ascites. Magnetic resonance imaging (MRI) may have higher accuracy for detecting HCC, especially early HCC.","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 1","pages":"113 - 118"},"PeriodicalIF":0.0,"publicationDate":"2022-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45976239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocellular carcinoma incidence in chronic hepatitis C patients according to sustained virological response (SVR) with interferon-based therapies and baseline characteristics","authors":"Tuul Purevsambuu,&nbsp;Simona Bota,&nbsp;Florian Hucke,&nbsp;Harald Hofer,&nbsp;Peter Ferenci,&nbsp;Wolfgang Sieghart,&nbsp;Markus Peck-Radosavljevic","doi":"10.1002/lci2.52","DOIUrl":"10.1002/lci2.52","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death worldwide with increasing incidence. Effective antiviral treatment for chronic hepatitis C (CHC) became available in the last 7 years but despite the WHO Hepatitis elimination targets, they are not universally available today in all regions for all the patients, indicating still a bleak outlook for CHC-associated HCC in the next decades.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To assess the HCC incidence in relation to interferon (IFN)-based antiviral treatment response and baseline characteristics of a large cohort of chronic hepatitis C (CHC) patients from a single institution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively collected data of CHC patients, who were diagnosed between 1989 and 2011 and treated at the AKH-University Hospital of Vienna before the introduction of direct-acting antiviral (DAA) only therapy. We analysed the HCC incidence in patients with a sustained virological response (SVR) and without SVR according to the patients' baseline characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our study included 2134 patients, who were treated or not treated with IFN-based antiviral treatment and had long-term follow-up available. The overall HCC incidence in this cohort was 6.2% (132 HCC cases over a median follow-up period of 9 years). According to the baseline fibrosis stage, the overall HCC incidence was: 1.1% in patients with baseline fibrosis stage F0-2, 8.2% in F3 and 20.6% in F4 patients. The HCC incidence was significantly higher in non-SVR and no-treatment group as compared with SVR patients: 12.4% vs 1.9%, <i>P</i> &lt; .0001, 7.3% vs 1.9%, <i>P</i> &lt; .0001. In multivariate analysis, lower platelet count (odds ratio-OR = -0.1, 95% CI: 0.15-0.63), for the SVR group and presence of cirrhosis (OR = 3.6, 95% CI: 1.59-8.17), ALBI grade &gt;=2 (OR = 2.3, 95% CI: 1.0-5.3) for the non-SVR group were independently associated with HCC occurrence. For the group of patients with no treatment, the only predictor for HCC was high baseline alpha-fetoprotein values (OR = 10.2, 95% CI: 2.2-47.9).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The achievement of SVR significantly reduces the risk for HCC occurrence during long-term follow-up. However, the risk remains high in successfully treated patients with low platelet count and in patients who did not achieve SVR with more adv","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 2","pages":"53-62"},"PeriodicalIF":0.0,"publicationDate":"2022-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.52","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48941417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour burden score and immune-related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors","authors":"Eleonora Di Carlo,&nbsp;Antonio D'Alessio,&nbsp;Antonella Cammarota,&nbsp;Valentina Zanuso,&nbsp;Tiziana Pressiani,&nbsp;Silvia Bozzarelli,&nbsp;Giuseppe Ferrillo,&nbsp;Giulia Vatteroni,&nbsp;Vittorio Pedicini,&nbsp;Laura Giordano,&nbsp;Nicola Personeni,&nbsp;Lorenza Rimassa","doi":"10.1002/lci2.51","DOIUrl":"10.1002/lci2.51","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background &amp; Aims</h3>\u0000 \u0000 <p>Treatment of hepatocellular carcinoma (HCC) with immune checkpoint inhibitors (ICIs) is associated with the development of hepatic immune-related adverse events (HIRAEs). We aimed to evaluate the role of baseline hepatic tumour burden, measured with the tumour burden score (TBS), in the development of HIRAEs and survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective observational cohort study on 93 patients treated with ICIs at IRCCS Humanitas Research Hospital, of which 42 for advanced HCC (Cohort 1) and 51 for non-HCC cancers with liver metastases developed prior to immunotherapy initiation (Cohort 2). We assessed the baseline tumour burden using TBS: TBS² = (maximum tumour diameter)² + (number of liver lesions)².</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the cohort of patients with HCC, 18 patients (42.86%) developed any grade (G) HIRAEs, of which eight (19.05%) were G ≥ 2. Patients who developed any-grade HIRAEs had a higher median TBS compared to patients with no HIRAEs (10.95 vs 5.85; <i>P</i> = .11). Baseline TBS correlated with the development of any-grade HIRAEs with marginal statistical significance (odds ratio [OR] 1.37, <i>P</i> = .08). Median OS was not influenced by TBS or by the development of HIRAEs.</p>\u0000 \u0000 <p>In the cohort of non-HCC patients, 18 patients (35.29%) developed any-grade HIRAEs, of which three (5.88%) were G ≥ 2. Baseline TBS did not correlate with the development of any-grade HIRAEs (OR 1.01), and median OS was not influenced by TBS or HIRAEs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Despite the limited sample size and the absence of statistical significance, our study suggested a possible association between baseline TBS and the development of any-grade HIRAEs in the HCC cohort. Future evaluation of larger cohorts is needed to corroborate these findings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 2","pages":"63-71"},"PeriodicalIF":0.0,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.51","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41827309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced hepatocellular carcinoma: Impact of systemic treatments on health-related quality of life and patient-reported outcomes","authors":"Giacomo Aimar,&nbsp;Donatella Marino,&nbsp;Clizia Zichi,&nbsp;Teresa Gamba,&nbsp;Andrea Caglio,&nbsp;Francesca De Vita,&nbsp;Elisa Sperti,&nbsp;Massimo Di Maio","doi":"10.1002/lci2.50","DOIUrl":"10.1002/lci2.50","url":null,"abstract":"<p>In the past years, treatment options for advanced hepatocellular carcinoma (HCC) have thriven. Although globally recognised, the patient-reported outcomes (PROs) are often underused and quality of life (QoL) results are underreported in many phase III trials. We performed a systematic review to describe the prevalence of QoL inclusion and heterogeneity in QoL reporting in published phase III trials of systemic treatment in advanced HCC. Twenty-one publications were identified: 12 (57.1%) in first line setting, eight (38.1%) in second line and only one (4.7%) in second and further lines. In 14 trials (66.6%), Qol was included in the analysis as a secondary or tertiary endpoint but only in nine (47.4%) cases Qol results were published in the main paper. QoL data are lacking in a significant proportion of published phase III trials in advanced HCC. The methodology of QoL analysis is heterogeneous for type of instruments, analysis and presentation of results.</p>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 2","pages":"90-98"},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.50","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46866386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}